A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review

BACKGROUND AND AIMS: Interferon beta (IFNβ) is a well‐established first‐line therapy for relapsing–remitting multiple sclerosis (RRMS) patients and remains the most widely prescribed agent. Atypical hemolytic uremic syndrome (aHUS) represents a rare but severe adverse effect (AE) that could occur ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Mosè, Manni, Alessia, Caputo, Francesca, Trojano, Maria, Paolicelli, Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821561/
https://www.ncbi.nlm.nih.gov/pubmed/33325640
http://dx.doi.org/10.1002/brb3.1930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821561/
https://www.ncbi.nlm.nih.gov/pubmed/33325640
http://dx.doi.org/10.1002/brb3.1930

Ejemplares similares